Many articles dealing with individual cell lag phase determination assume that growth, when observed, comes from one cell. This assumption is not in agreement with the Poisson distribution, which uses the probability of growth in a sample to predict how many samples contain one, two, or some other number of cells. This article analyses and compares different approaches to improve the accuracy o...

Alternative discretization and solution procedures are developed for the 1-D dual phase-lag (DPL) equation, a partial differential equation for very short time, microscale heat transfer obtained from a delay partial differential equation that is transformed to the usual non-delay form via Taylor expansions with respect to each of the two time delays. Then in contrast to the usual practice of de...

dual phase steels with different martensite volume fraction and morphology were tensile tested at a temperature range of 25 to 5500c. stress-strain curves of all steels showed serration flow at temperatures of 250 and 3500c, and smooth flow at the other temperatures. both yield and ultimate tensile strengths increased with increasing testing temperature up to about 4500c and then decreased at h...

Dual phase steels with different martensite volume fraction and morphology were tensile tested at a temperature range of 25 to 5500C. Stress-strain curves of all steels showed serration flow at temperatures of 250 and 3500C, and smooth flow at the other temperatures. Both yield and ultimate tensile strengths increased with increasing testing temperature up to about 450<sup...

Inhibitory receptors on immune cells are pivotal regulators of immune escape in cancer. Among these inhibitory receptors, CTLA-4 (targeted clinically by ipilimumab) serves as a dominant off-switch while other receptors such as PD-1 and LAG-3 seem to serve more subtle rheostat functions. However, the extent of synergy and cooperative interactions between inhibitory pathways in cancer remain larg...

Inhibitory receptors on immune cells are pivotal regulators of immune escape in cancer. Among these inhibitory receptors, CTLA-4 (targeted clinically by ipilimumab) serves as a dominant off-switch while other receptors such as PD-1 and LAG-3 seem to serve more subtle rheostat functions. However, the extent of synergy and cooperative interactions between inhibitory pathways in cancer remain larg...

Inhibitory receptors on immune cells are pivotal regulators of immune escape in cancer. Among these inhibitory receptors, CTLA-4 (targeted clinically by ipilimumab) serves as a dominant off-switch while other receptors such as PD-1 and LAG-3 seem to serve more subtle rheostat functions. However, the extent of synergy and cooperative interactions between inhibitory pathways in cancer remain larg...